SCHEMBL4426203

SCHEMBL4426203

Cc1csc(S(=O)(=O)N2CC3C(C2)C3C(=O)Nc2ccc(N3CCOCC3)c(F)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
HTT P42858 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
MTOR P42345 1/20 0.40
EPHX2 P34913 1/20 0.40
PDE7A Q13946 1/20 0.39
MAPK1 P28482 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4417870 0.86 ALDH1A1 (0.53) KMT2ANPC1RAB9AALDH1A1HPGD
SCHEMBL4426207 0.84 MAOB (0.40) KMT2ANPC1RAB9AALDH1A1HPGD
SCHEMBL4552446 0.81 EPHX2 (0.47) KMT2ARAB9AALDH1A1HPGDHTT
SCHEMBL4417779 0.80 KMT2A (0.49) KMT2ANPC1RAB9AALDH1A1HPGD
SCHEMBL4413581 0.80 RAB9A (0.53) KMT2ARAB9AALDH1A1HPGDNPSR1
SCHEMBL6501565 0.80 LMNA (0.48) KMT2ANPC1RAB9AALDH1A1HPGD
SCHEMBL4414453 0.79 EPHX2 (0.54) KMT2ANPC1RAB9AALDH1A1HPGD
SCHEMBL4421562 0.79 ALDH1A1 (0.47) KMT2ANPC1RAB9AALDH1A1HPGD
SCHEMBL4423583 0.79 ALDH1A1 (0.49) KMT2ANPC1RAB9AALDH1A1HPGD
SCHEMBL4415023 0.79 SLC6A9 (0.48) KMT2AALDH1A1HPGDHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 KMT2A 1892/4885NPC1 301/4885RAB9A 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.